Loss of heterozygosity at chromosome 9p21 in primary neuroblastomas: Evidence for two deleted regions

Cancer Genetics and Cytogenetics

Volumn 96, Issue 2, 1997, Pages 134-139

  Marshall, Brendan ^a,c   Isidro, Gloria ^a   Martins, Antonio Gentil ^b   Boavida, Maria Guida ^a  

^a NATIONAL INSTITUTE OF HEALTH DR RICARDO JORGE   (Portugal)

^b INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; PROTEIN P16;

ARTICLE; CENTROMERE; CHILD; CHROMOSOME 1P; CHROMOSOME 9P; CHROMOSOME MARKER; CHROMOSOME POLYMORPHISM; CLINICAL ARTICLE; CONTROLLED STUDY; GENE DELETION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MASS SCREENING; NEUROBLASTOMA; PORTUGAL; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

CARRIER PROTEINS; CELL CYCLE PROTEINS; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 9; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENETIC MARKERS; HETEROZYGOTE; HUMANS; NEUROBLASTOMA; SEQUENCE DELETION; TUMOR SUPPRESSOR PROTEINS;

EID: 0030839811     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(96)00300-7     Document Type: Article

References (49)

1. Young JL, Ries LG, Silverberg E, Horm JW, Miller RN (1986): Cancer incidence survival and mortality for children younger than 15 years of age. Cancer 56:598-602.
2. Biedler JL, Ross RA, Shanske S, Spengler BA (1980): Human neuroblastoma cytogenetics. In: Advances in Neuroblastoma Research. Evans AE, ed. Raven Press, New York, pp. 81-96.
3. Brodeur CM, Green AA, Hayes FA, Williams KJ, Williams DL, Tsiatis AA (1981): Cytogenetic features of human neuroblastomas and cell lines. Cancer Res 41:4678-4686.
4. Gilbert F, Balaban G, Moorhead P, Bianchi D, Schlesinger H (1982): Abnormalities of chromosome 1p in human neuroblastoma tumors and cell lines. Cancer Genet Cytogenet 7:33-42.
5. Weith A, Martinsson T, Cziepluch C, Bruderlein S, Amier LC, Berthold F, Schwab M (1989): Neuroblastoma consensus deletion maps to 1p36.1-2. Genes Chromosom Cancer 1:159-166.
6. Brodeur CM, Seeger RC, Schwab M, Varmus HE, Bishop JM (1984): Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224:1121-1124.
7. The I, Murthy AE, Hannigan GE, Jacoby LB, Menon AG, Gusella JF, Bernards A (1993): Neurofibromatosis type 1 mutations in neuroblastoma. Nature Genet 3:62-66.
8. Chang CL, Zhu X, Thoraval DH, Ungar D, Rawwas J, Hora N, Strahler JR, Hanash SM, Radany E (1994): nm23-H1 mutation in neuroblastoma. Nature 370:335-336.
9. Hiyama E, Hiyama K, Yokoyama T, Matsuura Y, Piatyszek MA, Shay JW (1995): Correlating telomerase activity levels with human neuroblastoma outcomes. Nature Med 1, 249-255.
10. Savalyeva L, Corvi R, Schwab M (1994): Translocation involving 1p and 17 is a recurrent genetic alteration of human neuroblastoma cells. Am J Hum Genet 55:334-340.
11. van Roy N. Laureys G, Cheng NC, Willem P, Opdenakker G, Versteeg R, Speleman F (1994): 1;17 translocations and other chromosome 17 rearrangements in human primary neuroblastoma tumors and cells lines. Genes Chromosom Cancer 10:103-114.
12. Caron H, van Sluis P, van Roy N, de Kraker J, Speleman F, Voute PA, Westerveld A, Slater R, Versteeg R (1994): Recurrent 1:17 translocations in human neuroblastoma reveal non-homologous mitotic recombination during S/G2 phase as a novel mechanism for loss of heterozygosity. Am J Hum Genet 55:341-347.
13. Fong C, White PS, Peterson K, Sapienza C, Cavanee WK, Kern SE, Vogelstein B, Cantor AB, Look T, Brodeur GM (1992): Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas. Cancer Res 52:1780-1785.
14. Maris JM, White PS, Beltinger CP, Sulman EP, Castleberry RP, Shuster JJ, Look AT, Brodeur GM (1995): Significance of chromosome 1p36 loss of heterozygosity in neuroblastoma. Cancer Res 55:4664-4669.
15. Caron H, van Sluis P, de Kraker J, Bokkerink J, Egeler M, Laureys G, Slater R, Westerveld A, Voute PA, Versteeg R (1996): Allelic loss of chromosome 1p as a predictor of unfavourable outcome in patients with neuroblastoma. New Engl J Med 334:225-230.
16. Caron H, van Sluis P, van Hoeve M, de Kraker J, Bras J, Slater R, Mannens M, Voute PA, Westerveld A, Versteeg R (1993): Allelic loss of chromosome 1p36 in neuroblastoma is of preferential maternal origin and correlates with N-myc amplification. Nature Genet 4:187-194.
17. Schleiermacher G, Peter M, Michon J, Hugot J-P, Vielh P, Zucker J-M, Magdelenat H, Thomas G, Pelattre O (1994): Two distinct regions on the short arm of chromosome 1 in neuroblastoma. Genes Chromosom Cancer 10:275-281.
18. Cheng NC. van Roy N, Chan A, Beitsma M, Westerveld A, Speleman F, Versteeg R (1995): Deletion mapping in neuroblastoma cell lines suggests two distinct tumour suppressor genes in the 1p35-36 region only one of which is associated with N-myc amplification. Oncogene 10:291-297.
19. Fong CT, Dracopoli NC, White PS, Merrill PT, Griffith RC, Houseman DE, Brodeur GM (1989): Loss of heterozygosity for the short arm of chromosome 1 in neuroblastomas: correlation with N-myc amplification. Proc Natl Acad Sci USA 86:3753-3757.
20. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Horsham K, Tavtigian SV, Skolnick MH (1994): A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-438.
21. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus J, McClure M, Ailken JF, Anderson DE, Bergman W, Frauts R, Goldgar DE, Green A, MacLennan R, Martin NG, Meyer LJ, Youl P, Zone JJ, Skolnick MH, Cannon-Albright LA (1994): Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet 8:22-26.
22. Mori T, Mire K, Ai T, Nishihara T, Mori S, Nakamura Y (1994): Frequent somatic mutation of the MTS1/CDK41 (multiple tumour suppressor/cyclin dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 54:3396-3401.
23. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PAT, Ally DS, Sheahen MD, Clark WH, Tacker MA, Dracopoli NC (1994): Germline p16 mutations in familial melanoma. Nature Genet 8:15-21.
24. Kamb A (1994): Role of a cell cycle regulator in hereditary and sporadic cancer. Cold Spring Harbor Symposia on Quantitative Biology Vol LIX, 39-47.
25. Takita J, Hagayashi Y, Kohno T, Shiseki M, Yamasuchi N, Haned R, Yamamoto K, Yokota J (1995): Allelotype of neuroblastoma. Oncogene 11:1829-1834.
26. Diaz MO, Rubin CM, Harden A, Ziemen S, Larsen RA, Le Beau MM, Rwoley JD (1990): Deletions of Interferon genes in acute lymphoblastic leukaemia. New Engl J Med 322:77-82.
27. Hagemeijer A, Versnel MA, van Dunen E, Moret M, Bouts MJ, van der Kwas TH, Hoogsteden HC (1990): Cytogenetic analysis of malignant mesothelioma. Cancer Genet Cytogenet 47:1-7.
28. Pederson MI, Bennet JW, Wang N (1986): Nonrandom chromosome structural aberrations and oncogene loci in human malignant melanoma. Cancer Genet Cytogenet 20:11-16.
29. James CD, He J, Carlbom. E, Nordenskjold M, Cavenee WK, Collins VP (1991): Chromosome 9 deletion mapping reveals interferon alpha and beta-1 gene deletions in human glial tumours. Cancer Res 51:1684-1690.
30. Vanni R, Scarpa RM, Nieddu M, Usai E (1988): Cytogenetic investigation on 30 bladder carcinomas. Cancer Genet Cytogenet 30:35-40.
31. Lukeis R, Irving L, Garson M, Hasthorpe S (1990): Cytogenetics of non-small cell lung cancer: Analysis of consistent, nonrandom abnormalities. Genes Chromosom Cancer 2:116-121.
32. Whang-Peng J, Knutsen T, Gazdar A, Steinberg SM, Oie H, Linnoila I, Mulshine J, Nau M, Minna JD (1991): Nonrandom structural and numerical chromosome changes in non small cell lung cancer. Genes Chromosom Cancer 3:168-174.
33. Cairns P, Shaw ME, Knowles MA (1993): Preliminary mapping of the deleted region of chromosome 9 in bladder cancer. Cancer Res 53:1230-1234.
34. Cairns P, Shaw ME, Knowles MA (1993): Initiation of bladder cancer may involve deletion of a tumour suppressor gene on chromosome 9. Oncogene 8:1083-1085.
35. Cairns P, Tokino K, Eby Y, Sidransky D (1994): Homozygous deletions of 9p21 in primary human bladder tumours detected by comparative multiplex polymerase chain reaction. Cancer Res 54:1422-1427.
36. Olopade OI, Buchhagen DL, Malik J, Sherman J, Nobori T, Bader S, Nau MM, Gazdar AF, Minna JD, Diaz MO (1993): Homozygous loss of Interferon genes defines the critical region on 9p that is deleted in lung cancers. Cancer Res 53:2410-2415.
37. Ruppert JM, Tokino K, Sidransky D (1993): Evidence for two bladder cancer suppressor loci on human chromosome 9. Cancer Res 53:5093-5098.
38. Knowles MA, Elder PA, Williamson M, Cairns JP, Shaw ME, Law MG (1994): Allelotype of human bladder cancer. Cancer Res 54:531-536.
39. Spruck CH, Gonzalez-Zulueta M, Shibata A, Simoneau AR, Lin M-F, Gonzales F, Tsai TC, Jones PA (1994): p16 gene in uncultured tumours. Nature 370:183-184.
40. Cairns P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, Tokino K, van der Riet P, Blaugrund JE, Sidransky D (1994): Rates of p16(MTS1) mutations in primary tumours with 9p loss. Science 265:415-416.
41. Puig S, Ruiz A, Lazaro C, Castel T, Lynch M, Palou J, Vilalta A, Weissenbach J, Mascaro J-M, Estivill X (1995): Chromosome 9p deletions in cutaneous malignant melanoma tumours: the minimal deleted region involves markers outside the p16 (CDKN1) gene. Am J Hum Genet 57:395-402.
42. INK4B gene) during tumour progression in a sporadic melanoma patient. Cancer Res 55:5531-5535.
43. Laird PW, Zijderveld A, Linders K, Rudnicki MA, faenisch R, Berns A (1991): Simplified mammalian DNA isolation procedure. Nucl Acids Res 19:4293.
44. Gyapy G, Morisette J, Vignal A, Dib C, Fizames C, Millaseau P," Marc S, Bernardi G, Lathrop M, Weissenbach J (1994): The 1993-94 Genethon human genetic linkage map. Nature Genet 7:246-339.
45. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter JL, Buckler A, Gabrielson E, Tockman M, Cho KR, Hedrick L, Bova GS, Isaacs W, Koch W, Schwab D, Sidransky D (1995): Frequency of homozygous deletion at p16 (CDKN2) in primary human tumours. Nature Genet 11:210-212.
46. Budowle B, Chakraborty R, Giusti AM, Eisenberg AJ, Allen RC (1991): Analysis of the VNTR locus D1S80 by high resolution PAGE. Am J Hum Genet 48:137-144.
47. Lauthier V, Mariat D, Vergnaud G (1992): CEB 15 detects a VNTR locus (Het:92%) on chromosome 1p. Hum Mol Genet 1:756.
48. Nobori T, Miura K, Wu DJ, Lois A, Takbayashi K, Carson DA (1994): Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753-756.
49. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC. Baylin SB, Sidransky D (1995): 5′CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Med 1:686-692.